AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase 4 study titled ‘A Prospective, Multi-Center Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, an Anti-HER2-Antibody Drug Conjugate in Indian Patients With Unresectable or Metastatic HER2-Positive Breast Cancer Who Have Received a Prior Anti-HER2-Based Regimen.’ The study aims to evaluate the safety profile of Trastuzumab Deruxtecan in Indian patients, providing crucial data for its use in this demographic.
Intervention/Treatment: The study tests Trastuzumab Deruxtecan, an anti-HER2-antibody drug conjugate administered via IV infusion. It is intended to treat patients with unresectable or metastatic HER2-positive breast cancer.
Study Design: This interventional study follows a single-group model with no masking, focusing on treatment as its primary purpose. It aims to provide insights into the safety of Trastuzumab Deruxtecan in the specified patient group.
Study Timeline: The study began on January 2, 2025, with the latest update submitted on July 25, 2025. These dates mark the study’s progression and the ongoing collection of safety data.
Market Implications: This study could influence AstraZeneca’s stock performance by reinforcing investor confidence in the company’s commitment to expanding its oncology portfolio. The focus on Indian patients may also enhance market penetration in emerging markets, potentially impacting competitor dynamics in the HER2-positive breast cancer treatment landscape.
The study is currently recruiting, with further details available on the ClinicalTrials portal.